TEVA’s TEV-408 posts positive Phase 2a topline in celiac disease
TEV-408 (anti-IL-15) reported positive Phase 2a topline results in celiac disease, including prevention of gluten-induced intestinal damage and improved symptoms after a single subcutaneous dose.
TEV-408 (anti-IL-15) posted positive Phase 2a topline results in celiac disease, with a single subcutaneous dose significantly preventing gluten-induced intestinal damage and improving symptoms. The asset was described as having a strong safety profile, multi-indication potential and a large market opportunity.